Public market insider buying at Profound Medical (PRN)

Public market insider buying at Profound Medical (T:PRN)

Arun Menawat, CEO and Director, acquired 8,100 Common Shares on a direct ownership basis at a price of $12.394USD on November 9th, 2021. This represents a $124,962 investment into the company's shares and an account share holdings change of 2.9%.

Profound Medical is in the Advanced Medical Equipment & Technology Sub Industry Group under the Healthcare Sector.

Profound Medical Corp. is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. The Company is commercializing TULSA-PRO, which is a technology that combines real-time magnetic resonance imaging (MRI), transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while protecting the urethra and rectum to help preserve the patient's natural functional abilities. The Company is also commercializing Sonalleve, which is a therapeutic platform for the treatment of uterine fibroids and palliative pain treatment of bone metastases.